ইউরোকিট এ আছে Potassium Citrate। ইউরোকিট এর কাজঃ
Renal Tubular Acidosis (RTA) With Calcium Stones: Potassium citrate is indicated for the management of renal tubular acidosis
Hypocitraturic Calcium Oxalate Nephrolithiasis Of Any Etiology: Potassium citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis
Uric Acid Lithiasis With Or Without Calcium Stones: Potassium citrate is indicated for the management of Uric acid lithiasis with or without calcium stones
|Urokit Tablet (Extended Release) 540 mg in bangla|
|ধরণঃ||ট্যাবলেট (এক্সটেন্ডেড রিলিজ)|
|চিকিৎসাগত শ্রেণিঃ||Prevention of repeated kidney stone formation|
|উৎপাদনকারীঃ||Eskayef Bangladesh Ltd|
|সর্বশেষ সম্পাদনাঃ||2020-11-21 18:15:00|
When ইউরোকিট is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, ইউরোকিট therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. The increased filtered load of citrate may play some role, however, as in small comparisons of oral citrate and oral bicarbonate, citrate had a greater effect on urinary citrate.
In addition to raising urinary pH and citrate, ইউরোকিট increases urinary potassium by approximately the amount contained in the medication. In some patients, ইউরোকিট causes a transient reduction in urinary calcium.
The changes induced by ইউরোকিট produce urine that is less conducive to the crystallization of stoneforming salts (calcium oxalate, calcium phosphate and uric acid). Increased citrate in the urine, by complexing with calcium, decreases calcium ion activity and thus the saturation of calcium oxalate. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate (brushite).
The increase in urinary pH also decreases calcium ion activity by increasing calcium complexation to dissociated anions. The rise in urinary pH also increases the ionization of uric acid to the more soluble urate ion. ইউরোকিট therapy does not alter the urinary saturation of calcium phosphate, since the effect of increased citrate complexation of calcium is opposed by the rise in pH-dependent dissociation of phosphate. Calcium phosphate stones are more stable in alkaline urine.
In the setting of normal renal function, the rise in urinary citrate following a single dose begins by the first hour and lasts for 12 hours. With multiple doses the rise in citrate excretion reaches its peak by the third day and averts the normally wide circadian fluctuation in urinary citrate, thus maintaining urinary citrate at a higher, more constant level throughout the day. When the treatment is withdrawn, urinary citrate begins to decline toward the pre-treatment level on the first day.
The rise in citrate excretion is directly dependent on the ইউরোকিট dosage. Following long-term treatment, ইউরোকিট at a dosage of 60 mEq/day raises urinary citrate by approximately 400 mg/day and increases urinary pH by approximately 0.7 units.
In patients with severe renal tubular acidosis or chronic diarrheal syndrome where urinary citrate may be very low (<100 mg/day), ইউরোকিট may be relatively ineffective in raising urinary citrate. A higher dose of ইউরোকিট may therefore be required to produce a satisfactory citraturic response. In patients with renal tubular acidosis in whom urinary pH may be high, ইউরোকিট produces a relatively small rise in urinary pH.
ইউরোকিট এ আছে Potassium Citrate 540 mg। ইউরোকিট খাওয়ার নিয়ম নিম্নরূপঃ
Dosing Instructions: Treatment with extended release potassium citrate should be added to a regimen that limits salt intake (avoidance of foods with high salt content and of added salt at the table) and encourages high fluid intake (urine volume should be at least two liters per day). The objective of treatment with ইউরোকিট is to provide ইউরোকিট in sufficient dosage to restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 or 7.0.
Monitor serum electrolytes (sodium, potassium, chloride and carbon dioxide), serum creatinine and complete blood counts every four months and more frequently in patients with cardiac disease, renal disease or acidosis. Perform electrocardiograms periodically. Treatment should be discontinued if there is hyperkalemia, a significant rise in serum creatinine or a significant fall in blood hemocrit or hemoglobin.
Severe Hypocitraturia: In patients with severe hypocitraturia (urinary citrate <150 mg/day), therapy should be initiated at a dosage of 60 mEq/day (30 mEq two times/day or 20 mEq three times/day with meals or within 30 minutes after meals or bedtime snack). Twenty-four hour urinary citrate and/or urinary pH measurements should be used to determine the adequacy of the initial dosage and to evaluate the effectiveness of any dosage change. In addition, urinary citrate and/or pH should be measured every four months. Doses of ইউরোকিট greater than 100 mEq/day have not been studied and should be avoided.
Mild To Moderate Hypocitraturia: In patients with mild to moderate hypocitraturia (urinary citrate > 150 mg/day) therapy should be initiated at 30 mEq/day (15 mEq two times/day or 10 mEq three times/day within 30 minutes after meals or bedtime snack). Twenty-four hour urinary citrate and/or urinary pH measurements should be used to determine the adequacy of the initial dosage and to evaluate the effectiveness of any dosage change. Doses of ইউরোকিট greater than 100 mEq/day have not been studied and should be avoided.
Nausea, vomiting, diarrhea, and stomach pain may occur. Taking it after meals will help prevent these side effects. An empty tablet shell may appear in your stool. This is harmless because your body has already absorbed the medication.
This drug may cause serious stomach or intestinal problems (e.g., bleeding, blockage, puncture). This medication may cause high potassium levels in the blood (hyperkalemia). A very serious allergic reaction to this drug is rare.
This medication should not be used ifpatient have (Addison's disease), current bladder infection, uncontrolled diabetes, severe heart disease (e.g., recent heart attack, heart damage), certain stomach/intestinal problems (diabetic gastroparesis, conditions decreasing gut movement, peptic ulcer, blockage), severe kidney disease (e.g., inability to make urine), potassium-restricted diet, high potassium levels, severe loss of body water (dehydration).
Before using this medication, tell your doctor or pharmacist your medical history, especially of: low calcium levels, severe diarrhea, heart problems (e.g., irregular heartbeat, heart failure), kidney disease, stomach/gut problems (e.g., irritable bowel), severe tissue damage (e.g., severe burns). Before having surgery, tell your doctor or dentist that you are taking this medication.
Pregnancy Category C. Animal reproduction studies have not been conducted. It is also not known whether ইউরোকিট can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ইউরোকিট should be given to a pregnant woman only if clearly needed.
Nursing Mothers: The normal potassium ion content of human milk is about 13 mEq/L. It is not known if ইউরোকিট has an effect on this content. ইউরোকিট should be given to a woman who is breast feeding only if clearly needed.
ইউরোকিট is contraindicated:
Pediatric Use: Safety and effectiveness in children have not been established.
Treatment Of Overdosage: The administration of potassium salts to persons without predisposing conditions for hyperkalemia rarely causes serious hyperkalemia at recommended dosages. It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration and characteristic electrocardiographic changes (peaking of T-wave, loss of P-wave, depression of S-T segment and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest.
Treatment measures for hyperkalemia include the following:
Lowering potassium levels too rapidly in patients taking digitalis can produce digitalis toxicity.
ইউরোকিট ট্যাবলেট (এক্সটেন্ডেড রিলিজ) এর দাম 0.00